Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant prostate cancer in oligometastasis (≤5). Hence, the investigators evaluate the results of the combination of two widely used treatments in prostate cancer: SBRT plus the 'standard of care' for patients with mCRPC, second-generation antiandrogens (abiraterone and enzalutamide). Primary objective: Determine the PRFS measured from the time of initiation of second-genera

Trial Details

NCT ID
NCT07717268
Phase
PHASE2
Sponsor
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • Xtandi
  • Zytiga® (Abiraterone Acetate)
  • SBRT
Locations (sample)
  • Zaragoza, Aragon, Spain|41.65606,-0.87734
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • L'Hospitalet de Llobregat, Barcelona, Spain|41.35967,2.10028
  • Bilbao, Basque Country, Spain|43.26271,-2.92528
  • Salamanca, Castille and León, Spain|40.96882,-5.66388

Key Eligibility Criteria

  • Patients with histologically prostate adenocarcinoma, confirmed with a biopsy.
  • Testosterone in biochemical castration ranges (testosterone \<50 ng/ml or 1.7 nmol/L) and documented progression: biochemical according to Phoenix …
  • Biochemistry progression confirmed according to Phoenix criteria, with testosterone in castration levels (testosterone \<50 ng/ml or 1.7 nmol/L).
  • Radiological confirmation (with choline-PET/CT or 68Ga-PSMA-PET/CT) of ≤5 node or bone metastasis, non-visceral, eligible to receive SBRT treatment…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →